Compare USCB & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USCB | EOLS |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 284.3M |
| IPO Year | 2021 | 2018 |
| Metric | USCB | EOLS |
|---|---|---|
| Price | $18.56 | $6.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $23.00 | $15.50 |
| AVG Volume (30 Days) | 74.9K | ★ 886.6K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 7.26 | 1.23 |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $26.46 | $13.27 |
| Revenue Next Year | $9.67 | $17.62 |
| P/E Ratio | $36.33 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $15.57 | $3.86 |
| 52 Week High | $20.79 | $10.62 |
| Indicator | USCB | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 55.97 |
| Support Level | $17.80 | $5.94 |
| Resistance Level | $18.82 | $6.40 |
| Average True Range (ATR) | 0.49 | 0.36 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 60.96 | 52.85 |
USCB Financial Holdings Inc is a bank holding company. Through its banking subsidiary, it offers relationship-based banking products, services, and solutions to a diverse set of clients in the local markets it operates in and international clients with U.S. banking needs. The Group's products and services offerings mainly include traditional deposit products, including commercial and consumer checking accounts, money market deposit accounts, savings accounts, etc.; e-banking services; title insurance policies for real estate transactions; and a variety of lending products such as small business loans, commercial real estate loans, business credit cards, etc.; and others. Geographically, its primary banking market is South Florida.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.